These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18576151)

  • 1. Methods for conversion of prion protein into amyloid fibrils.
    Breydo L; Makarava N; Baskakov IV
    Methods Mol Biol; 2008; 459():105-15. PubMed ID: 18576151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
    Baskakov IV; Bocharova OV
    Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and fibrillation of full-length recombinant PrP.
    Makarava N; Baskakov IV
    Methods Mol Biol; 2012; 849():33-52. PubMed ID: 22528082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
    Walsh P; Simonetti K; Sharpe S
    Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.
    Lührs T; Zahn R; Wüthrich K
    J Mol Biol; 2006 Mar; 357(3):833-41. PubMed ID: 16466741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation.
    Breydo L; Bocharova OV; Makarava N; Salnikov VV; Anderson M; Baskakov IV
    Biochemistry; 2005 Nov; 44(47):15534-43. PubMed ID: 16300402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.
    Tagliavini F; Forloni G; Colombo L; Rossi G; Girola L; Canciani B; Angeretti N; Giampaolo L; Peressini E; Awan T; De Gioia L; Ragg E; Bugiani O; Salmona M
    J Mol Biol; 2000 Jul; 300(5):1309-22. PubMed ID: 10903871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a spontaneously aggregating amyloid-forming variant of human PrP((90-231)) through phage-display screening of variants randomized between residues 101 and 112.
    Verma A; Sharma S; Ganguly NK; Majumdar S; Guptasarma P; Luthra-Guptasarma M
    Int J Biochem Cell Biol; 2008; 40(4):663-76. PubMed ID: 18023239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways.
    El Moustaine D; Perrier V; Smeller L; Lange R; Torrent J
    FEBS J; 2008 May; 275(9):2021-31. PubMed ID: 18355314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
    Leliveld SR; Stitz L; Korth C
    Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism at residue 129 modulates the conformational conversion of the D178N variant of human prion protein 90-231.
    Apetri AC; Vanik DL; Surewicz WK
    Biochemistry; 2005 Dec; 44(48):15880-8. PubMed ID: 16313190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion Protein Prolines 102 and 105 and the Surrounding Lysine Cluster Impede Amyloid Formation.
    Kraus A; Anson KJ; Raymond LD; Martens C; Groveman BR; Dorward DW; Caughey B
    J Biol Chem; 2015 Aug; 290(35):21510-22. PubMed ID: 26175152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways.
    Natalello A; Prokorov VV; Tagliavini F; Morbin M; Forloni G; Beeg M; Manzoni C; Colombo L; Gobbi M; Salmona M; Doglia SM
    J Mol Biol; 2008 Sep; 381(5):1349-61. PubMed ID: 18619462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does domain replacement affect fibril formation of the rabbit/human prion proteins.
    Yan X; Huang JJ; Zhou Z; Chen J; Liang Y
    PLoS One; 2014; 9(11):e113238. PubMed ID: 25401497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.
    Tahiri-Alaoui A; James W
    Protein Sci; 2005 Apr; 14(4):942-7. PubMed ID: 15741327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.